Grifols Alzheimer’s vaccine appears safe, but efficacy unclear, in PhII study
2023-10-24
临床2期临床结果疫苗
An experimental Alzheimer’s vaccine that stimulates the immune system to remove forms of amyloid proteins that accumulate in blood vessels appeared safe in a study of patients with mild cognitive impairment or mild Alzheimer’s disease.
People in the Phase II, 134 patient study were assessed a year after they received the first of 6 shots. When measured on a common test for cognitive impairment called the Mini-Mental State Examination (MMSE), their disease slowed by a maximum of 38% in people who got the vaccines compared to placebo. That result was statistically significant. But a later review at 18 months and 24 months, which showed an 18% slowing of disease, was not.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
-靶点
-药物
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。